The 4 linked references in paper Andrey Pavlysh Vladislavovich, Aleksei Kolbin Sergeevich, Roman Gapeshin Andreevich, Stanislav Malyshev Mikhailovich, Андрей Павлыш Владиславович, Алексей Колбин Сергеевич, Роман Гапешин Андреевич, Станислав Малышев Михайлович (2015) “Причины сложности проведения фармакоэкономического анализа для орфанных лекарств. Пути решения // REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS” / spz:neicon:pharmacoeconomics:y:2015:i:2:p:3-10

  1. Denis A., Mergaert L., Fostier C., et al. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010; 97: 173-179.
  2. Drummond M., Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014; 15: 335-340.
  3. Picavet E., Dooms M., Cassiman D., et al. Drugs for rare diseases: Influence of orphan designation status on price. Appl Health Econ Health Policy. 2011; 9 (4): 275-279.
  4. Simoens S., Picavet E., Dooms M., et al. Cost-Effectiveness Assessment of Orphan Drugs. Appl Health Econ Health Policy. 2013; 11: 1-3.